Market Overview

Amazon's Pharma Aspirations: Cowen Finds No New License Applications

Share:
Amazon's Pharma Aspirations: Cowen Finds No New License Applications
Related AMZN
Gene Munster Talks Apple, Amazon-Target, Tesla On PreMarket Prep
Loud And Clear: Sonos Boasts High Demand In Q4 Print
Passive Investing Madness: 50,000 Stocks Vs 3.7 Million Indexes (TalkMarkets)

Is Amazon.com, Inc. (NASDAQ: AMZN) looking to enter the pharmacy space? A review of statewide pharmacy licenses answers the pressing question, according to Cowen. 

The Analyst

Cowen's Charles Rhyee does not directly cover Amazon's stock. The firm has an Outperform rating and $1,500 price target for Amazon. 

The Thesis

An analysis of state pharmacy boards indicates that Amazon isn't actively pushing itself into the pharma space, Rhyee said in a Friday report. (See the analyst's track record here.) 

Amazon obtained wholesaler licenses in 13 states, something the company said is needed to sell professional medical products, the analyst said. The most recent data shows that Amazon has allowed some of its licenses to expire and has only one remaining., he said. Perhaps more important, Amazon hasn't filed for any new wholesale or retail licenses in any of the states where it previously held licenses or had none.

"Until we begin to see more specialized licenses, such as those allowing AMZN to handle controlled substances, we think the competitive threat to the supply chain in the near-term remains low," Rhyee said. 

Cowen's John Blackledge said in November that Amazon's opportunity in the pharmacy space isn't as lucrative as many assume.

Rhyee said Amazon posted a job listing on its website for an experienced HIPAA professional, which isn't indicative of a major push into the pharmacy space. The listing is likely intended to find an expert who can help Amazon explore the multiple possibilities of entering the health care space, but with a "more diligent approach" to compliance, he said. 

Price Action

Shares of Amazon were trading up 0.35 percent at $1,297.85 at the time of publication Friday. 

Related Links:

Amazon Could Partner With UnitedHealth For Pharmacy Unit By Thanksgiving

Amazon Pharmacy Rumors Heating Up Again: Here's What We Know

Latest Ratings for AMZN

DateFirmActionFromTo
Oct 2018JefferiesMaintainsBuyBuy
Oct 2018Bank of AmericaMaintainsBuyBuy
Oct 2018BarclaysMaintainsOverweightOverweight

View More Analyst Ratings for AMZN
View the Latest Analyst Ratings

Posted-In: Amazon Pharmacy Charles Rhyee Cowen HealtchareAnalyst Color Health Care Analyst Ratings General Best of Benzinga

 

Related Articles (AMZN)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
LXFTKeyBancDowngrades0.0
CPAImperial CapitalDowngrades68.0
PRMWImperial CapitalInitiates Coverage On18.0
TGTKeyBancInitiates Coverage On110.0
QCOMMorgan StanleyUpgrades0.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

Snap Under Fire In The Headlines; Investors Shrug

Upcoming Netflix Earnings: Subscriber Growth And Price Hikes In Focus